What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @RichardPAConway: @SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe

      Richard Conway RichardPAConway

      4 years ago
      @SattuiSEMD presents @rheum_covid data on COVID-19 outcomes in vasculitis/PMR. High rates of severe outcomes, particularly for AAV and GCA (mortality >20% for both). Multiple factors associated with outcomes (see below). Abstr#952 #ACR21 @RheumNow #ACRBest https://t.co/0lw1QhuJct
      RT @swethaann23: Novel study exploring microbial differences in MZ twins discordant for psoriatic disease

      ⭐️Ruminoc

      swethaann23 swethaann23

      4 years ago
      Novel study exploring microbial differences in MZ twins discordant for psoriatic disease ⭐️Ruminococcus 🔽/❎ Gut of Ps pts and maybe associated with Ps Dis ⭐️NL skin scalp of Psoriatic pts 🔽 microbial diversity compared to unaffected twins Abst#0944 #ACR21 #ACRBest @RheumNow
      RT @RichardPAConway: Dr Manasson presents on microbiome differences between monozygotic twins discordant for psoriatic d

      Richard Conway RichardPAConway

      4 years ago
      Dr Manasson presents on microbiome differences between monozygotic twins discordant for psoriatic disease. Differences seen in gut (Ruminococcus virtually absent in psoriatic) and scalp non-lesional skin microbiomes Abstr#0944 #ACR21 @RheumNow https://t.co/8Ch0M4dwUH
      RT @RHEUMarampa: Interim analysis of real world data on AQUILA (Dr Uta Kiltz et al): how gender affects SEC tx and reten

      sheila RHEUMarampa

      4 years ago
      Interim analysis of real world data on AQUILA (Dr Uta Kiltz et al): how gender affects SEC tx and retention rates: 🔷Improvement in BASDAI, PGA, global fnxn & depressive mood - similar in both ♂️&♀️ 🔷High SEC retention rates irrespective of gender @RheumNow #ACR21 abs909 https://t.co/rXa6ELXDJo
      RT @RichardPAConway: Dr Mahajan on lung disease in early RA. Common, airway disease in 60%, parenchymal disease in 30%.

      Richard Conway RichardPAConway

      4 years ago
      Dr Mahajan on lung disease in early RA. Common, airway disease in 60%, parenchymal disease in 30%. But minimal/no progression over 1 year which is reassuring. Abstr#574 #ACR21 @RheumNow https://t.co/s9r06MSStF
      RT @drdavidliew: So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COV

      David Liew drdavidliew

      4 years ago
      So important for our systemic vasculitis & PMR pts, @rheum_covid data highlighting the outsized COVID-19 risks they face. Thanks @SattuiSEMD @RichardPAConway @EBRheum in particular for driving forward this badly needed work! #ACR21 ABST0952 @RheumNow https://t.co/L7XS9OblxI https://t.co/LYxR1WUlhM
      RT @KDAO2011: Dr. P Crow #PhilipHenchLecture: from LE cell to IFN:
      LE cell definition:
      👉substance in plasma
      👉nucl

      TheDaoIndex KDAO2011

      4 years ago
      Dr. P Crow #PhilipHenchLecture: from LE cell to IFN: LE cell definition: 👉substance in plasma 👉nuclear material from WBCs altered by the plasma factor 👉active phagocytic cells engulf the altered material #ACR21 @rheumnow https://t.co/jE9wnct6lP
      RT @ericdeinmd: Jorge Plutzky giving a cardiologist perspective at #ACR21. "We've gone from lower is better, to lowest i

      Eric Dein ericdeinmd

      4 years ago
      Jorge Plutzky giving a cardiologist perspective at #ACR21. "We've gone from lower is better, to lowest is best" on LDL lowering. PCSK9 inhibitors have changed the game. @rheumnow https://t.co/oaBE99beSA
      RT @RichardPAConway: MUC5B and RA-ILD. Dr McDermott @jeffsparks show that MUC5B is associated with RA-ILD, older age at

      Richard Conway RichardPAConway

      4 years ago
      MUC5B and RA-ILD. Dr McDermott @jeffsparks show that MUC5B is associated with RA-ILD, older age at RA diagnosis, and ILD within 5 years of RA onset. Is this a different disease to other RA or modulation by the promotor variant? Abstr#0576 #ACR21 @RheumNow https://t.co/r2fQqxVY6N
      RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by Rhe

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
      NrAxSpA progression to AxSpA: Dr. Rachel Tate
      4 years ago
      To Clot or Not to Clot: Drs. Janet Pope and Jeffrey Sparks
      4 years ago
      bathroom scale
      The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis
      4 years ago
      In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials. We often make our choices based on minor hints from clinical features, comorbidities, or cost considerations.
      RT @RHEUMarampa: Interesting study by @DrPoddubnyy et al. looking into the efficacy of SEC on HLAB27 subtypes (post hoc

      sheila RHEUMarampa

      4 years ago
      Interesting study by @DrPoddubnyy et al. looking into the efficacy of SEC on HLAB27 subtypes (post hoc analysis of SKIPPAIN trial) ➡ SEC effective for both HLAB27+ and - grps ➡ Significant response seen among HLAB27+ and HLAB27 homozygous pts @RheumNow #ACR21 abs0917 https://t.co/St37kdGY65
      RT @RichardPAConway: And here is ORAL-Surveillance, small increase in MACE and malignancy with tofacitinib vs TNFi. 1 ex

      Richard Conway RichardPAConway

      4 years ago
      And here is ORAL-Surveillance, small increase in MACE and malignancy with tofacitinib vs TNFi. 1 extra MACE per 319-567 patient years, 1 extra malignancy per 275 patient years. Abstr#0831 #ACR21 @RheumNow https://t.co/wMJnspTTBy

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×